KR20210130603A - Food Composition for Improving Lung Function, Comprising Green Tea Extract, Bellflower Extract and Propolis Extract - Google Patents

Abstract

The present application relates to a food composition for improving lung function comprising a green tea extract, Platycodon grandiflorus, and propolis. The food composition for improving lung function according to one aspect of the present invention exhibits a body fine dust discharge/detoxification effect and a body heavy metal discharge/detoxification effect.

Description

Food composition for improving lung function comprising green tea extract, bellflower extract and propolis extract {Food Composition for Improving Lung Function, Comprising Green Tea Extract, Bellflower Extract and Propolis Extract}

The present invention relates to a food composition for improving lung function comprising a green tea extract, a bellflower extract and a propolis extract.

The lungs take in oxygen from the air into the blood and discharge carbon dioxide, a waste product from the blood, into the air. In addition to respiration, the lungs have the function of regulating body temperature by dissipating heat through respiration, and maintaining the balance of acids and bases in the body. Pulmonary diseases include asthma, bronchitis, pneumonia, chronic obstructive pulmonary disease, pulmonary tuberculosis, lung cancer, and the like. The causes of these lung diseases are known as smoking, soot, fine dust, bacteria, and viruses. In addition, hypoxia due to lung disease may cause arrhythmia, heart failure, and pulmonary arterial hypertension, which may lead to depression, sleep disturbance, osteoporosis, general weakness, and the like.

Meanwhile, the public's interest in the lungs is increasing due to the onset of diseases caused by fine dust and corona virus. Particulate matter is a particulate complex contaminant having various sizes, compositions, and sources of generation. Generally, dust suspended in the air with a diameter of 10 μm or less is called PM10, and dust with a diameter of 2.5 μm or less. is called ultrafine dust (PM2.5), and particles smaller than 0.1 μm are called ultrafine dust (PM0.1). The causes of occurrence can be divided into anthropogenic sources emitted during the combustion of fossil fuels such as coal or oil, and sources caused by the natural environment itself, such as yellow sand, volcanic ash, and forest fires. The composition of such fine dust is very complex and diverse, and it is known that the health risk varies depending on the particle size, surface area, and chemical composition. Fine dust and yellow dust stimulate the airways and cause respiratory diseases such as cough, sputum, and inflammation. In particular, since fine dust contains various carcinogens and heavy metals, it can seriously affect the human body, such as cardiovascular and brain diseases, dementia, premature birth, and fetal malformations. Accordingly, although a method for preventing and treating inflammatory diseases, fine dust and heavy metal emission due to fine dust has been proposed, it is difficult to present a clear solution.

Republic of Korea Patent No. 10-2058618 describes a composition for preventing or treating respiratory diseases induced by fine dust using a plant extract as an active ingredient. The prior art relieves inflammation of the respiratory tract and lungs caused by fine dust, but does not provide an effect of discharging fine dust or heavy metals that have been introduced into the body. Therefore, there is an urgent need to develop a new therapeutic agent for improving lung function in a more diversified and complex manner.

Accordingly, the present inventors prepared a food composition for improving lung function, including green tea, bellflower, and propolis, while researching a food composition for improving lung function. In particular, by using green tea, bellflower, and propolis, which have effects related to improving lung function and lung disease, a composition containing a natural extract was prepared and optimal extraction conditions of the active ingredient were established, so that the composition containing the natural extract has the effect of emitting fine dust and heavy metals. found to have and completed the present invention.

One technical problem to be achieved by the present invention is to provide a food composition for improving lung function comprising a green tea extract, a bellflower extract and a propolis extract.

Another technical problem to be achieved by the present invention is to provide a pharmaceutical composition for preventing or treating lung disease, including a green tea extract, a bellflower extract, and a propolis extract.

The technical problems to be achieved by the present invention are not limited to the technical problems mentioned above, and other technical problems not mentioned can be clearly understood by those of ordinary skill in the art to which the present invention belongs from the description below. There will be.

In order to achieve the above technical problem, an embodiment of the present invention,

It provides a food composition for improving lung function comprising a green tea extract, a bellflower extract and a propolis extract.

In an embodiment of the present invention, the green tea extract, the bellflower extract, and the propolis extract are 1 to 3 parts by weight, 2.5 to 4.5 parts by weight, and 0.01 to 0.1 parts by weight to provide a food composition for improving lung function. .

In an embodiment of the present invention, the food composition may additionally include a mixed extract comprising maekmundong, ginseng, ragweed, and Tobokryeong, and the mixed extract may contain 1 to 3 parts by weight.

In an embodiment of the present invention, the mixed extract may include maekmundong, ginseng, ragweed and tobokryeong in a weight ratio of 0.5 to 1.5: 0.5 to 1.5: 0.5 to 1.5: and 0.5 to 1.5.

In order to achieve the above technical problem, another embodiment of the present invention is

It provides a pharmaceutical composition for preventing or treating lung disease, comprising green tea extract, bellflower extract and propolis extract.

In an embodiment of the present invention, the pharmaceutical composition for preventing or treating lung disease may be for transpulmonary absorption.

According to an embodiment of the present invention, the composition comprising the green tea extract, bellflower extract and propolis extract of the present invention exhibits an effect of excreting fine dust in the body and an effect of excreting heavy metals in the body. Accordingly, the composition of the present invention can be utilized as a food composition and a pharmaceutical composition. In particular, the pharmaceutical composition according to the present invention may be formulated to enable transpulmonary absorption in the form of an oral spray.

It should be understood that the effects of the present invention are not limited to the above-described effects, and include all effects that can be inferred from the configuration of the invention described in the detailed description or claims of the present invention.

1 is a schematic diagram showing a method for preparing a composition of the present invention according to an embodiment of the present invention.
2 is a diagram showing the ratio of neutrophils to the total number of cells according to the concentration of NiO nanoparticles as a result of a preliminary experiment on setting the concentration of NiO according to an embodiment of the present invention.
3 is a schematic diagram of a fine dust emission confirmation experiment according to an embodiment of the present invention.
4 is a view showing the total number of cells obtained from the lung lavage after administration of NiO nanoparticles according to an embodiment of the present invention.
5 is a diagram showing the amount of CINC-3 detected in lung lavage after administration of NiO nanoparticles according to an embodiment of the present invention.
6 is a schematic diagram of a heavy metal emission confirmation experiment according to an embodiment of the present invention.
7 is a diagram showing the results of ALT analysis in serum after administration of cadmium according to an embodiment of the present invention.
8 is a diagram showing AST analysis results in serum after administration of cadmium according to an embodiment of the present invention.
9 is a diagram showing the results of BUN analysis in serum after administration of cadmium according to an embodiment of the present invention.
10 is a diagram showing histopathological analysis of liver tissue on day 15 according to an embodiment of the present invention. A is G1, B is G4, C is G5, and D is G8.
11 is a diagram showing histopathological analysis of liver tissue on day 15 according to an embodiment of the present invention. A shows the results of G5 and B shows the results of G8.

Hereinafter, the present invention will be described with reference to the accompanying drawings. However, the present invention may be embodied in several different forms, and thus is not limited to the embodiments described herein. And in order to clearly explain the present invention in the drawings, parts irrelevant to the description are omitted, and similar reference numerals are attached to similar parts throughout the specification.

Throughout the specification, when a part is "connected (connected, contacted, coupled)" with another part, it is not only "directly connected" but also "indirectly connected" with another member interposed therebetween. "Including cases where In addition, when a part "includes" a certain component, this means that other components may be further provided without excluding other components unless otherwise stated.

The terms used herein are used only to describe specific embodiments, and are not intended to limit the present invention. The singular expression includes the plural expression unless the context clearly dictates otherwise. In this specification, terms such as "comprises" or "have" are intended to designate that the features, numbers, steps, operations, components, parts, or combinations thereof described in the specification exist, but one or more other features It should be understood that this does not preclude the existence or addition of numbers, steps, operations, components, parts, or combinations thereof.

The first aspect of the present application is

It provides a food composition for improving lung function comprising a green tea extract, a bellflower extract and a propolis extract.

Hereinafter, the food composition for improving lung function according to the first aspect of the present application will be described in detail.

The food composition for improving lung function of the present application includes a mixture of natural products described below in a certain ratio. Unless otherwise specified, natural products refer to those described herein or processed products thereof, and described natural products are mainly expressed by scientific names, but also include varieties and subspecies.

Bellflower (Gilkyung)

Gilgyeong (Platycodonis Radix) is an herbal medicine belonging to the genus Platycodon grandiflorum A. De Candolle of the bellflower family. The root is 10-15 cm long and 1-3 cm in diameter. The outer surface is grayish-brown, light brown or white, and there are concave marks on the upper end of which stems have been removed, and there are thin horizontal wrinkles and vertical grooves near them. Most of the roots, except for the root, have rough vertical wrinkles and horizontal grooves, and there are horizontal lines in the shape of shell eyes. The quality is firm but easy to break. The transverse section is not fibrous, the skin is slightly thinner than the xylem, almost white, with several pits, and the cambium area is brown. The neck is white to light brown, and the tissue is slightly denser than the skin. When the cross section of this drug is viewed under a microscope, the cork layer is yellowish-brown, but most of it has already been removed. The sergeant is wide and the outer sergeant line is curved, and the sergeant group is mostly depressed and decadent. The ducts are scattered in clusters and contain yellowish-brown granular material. Among the officers in the back, related groups are arranged together with the officers. The cambium forms a ring, and the xylem has a wide water line, and the conduit is polygonal, and one or several are arranged radially. This medicine has a slight characteristic odor, and the taste is mild at first and bitter and bitter afterward. It is used as a medicine for neuralgia and tonsillitis, has expectorant, antitussive, analgesic, sedative, and antipyretic action, and is used as an anti-inflammatory analgesic and antitussive expectorant.

green tea

Green tea is produced by the tea tree ( Camellia sinensis L. O Kuntze), a drink made from young leaves, and is a favorite drink not only in Asia but also around the world. The car split into two smaller Chinese (Camellia sinensis L. var. Sinesis) and fermented tea Oh Trailokya (Camellia sinensis L. var. Assamica) leaf which is mainly used in the big wide leaves are used mainly in the traditional tea Asian origin. The tea tree is an evergreen bush. The root extends straight down and is 2-4 m deep, and the side root is 15-20 cm long, and there are many thin roots. The leaves vary greatly depending on the variety or location, but they are alternate phyllotaxis and have a long oval shape with a length of 6-20 cm and a width of 3-4 cm. The quality of the leaves is hard, a little thick, and the surface is glossy. The flowers are white or light pink in October-November, and 1 to 3 flowers hang from the leaf axil or the tip of the branch. The fruits are capsules, round, and have a grain, and they start to grow in the spring of the following year and ripen in the fall, so flowers and fruits can be seen at the same time. As the fruit ripens, it bursts to reveal hard brown seeds. Green tea leaves are picked and steamed or hot air inactivated oxidase and then dried. These green tea seeds contain caffeine, oil 22% (in the seeds 18%), and theasaponin (C57H90O26). Theasaponin is hydrolyzed into theasapogenol (C18H34O7), glucuronic acid (C18H34O7), galactose, arabinose, xylose, and angelic acid. The seeds also have 33% starch, 8.5% protein. Stems, roots and seeds contain steroid saponins, especially in seeds (9-10%).

propolis

Propolis is a substance such as resin extracted from various kinds of trees and herbs for survival and reproduction by bees, attached to their hind legs, collected by bees, and then mixed with their own saliva to interact with enzymes in saliva. A generic term for a complex of various high molecular polymers produced by the reaction, the main component of which is flavonoids. Flavonoids include anthoxanes such as flavones, flavonones, flavonols, flavanols, flavanones and isoflavones, and sugar-bound glycosides, hundreds of anthocyanins and sugar-bound glycosides, catechins as tannins and leucoxancin.

As used herein, the term "extract" refers to a preparation obtained by squeezing a herbal medicine with an appropriate leachate and evaporating the leachate, and is not limited thereto. It may be a dried product obtained by drying, a crude product thereof, or a purified product. The extract of the present application can be prepared using general extraction methods, separation and purification methods known in the art. The extraction method is not limited thereto, but preferably, methods such as hot water extraction, hot water extraction, cold extraction, reflux cooling extraction, or ultrasonic extraction may be used.

The extract of the present invention can be prepared by fractionation by adding a fractionation solvent to the extract prepared by extraction with an extraction solvent or extraction with an extraction solvent. The extraction solvent is not limited thereto, but a solvent such as water, an organic solvent, or a mixture thereof may be used, and the organic solvent is an alcohol having 1 to 4 carbon atoms, a polar solvent such as ethyl acetate or acetone, hexane or A non-polar solvent of dichloromethane or a mixed solvent thereof may be used. In addition, preferably water, an alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof may be used, and more preferably water or alcohol may be used. In one embodiment of the present invention, an extract using alcohol as the solvent was prepared.

Additionally, the extract of the present invention may be an extract extracted by heating a natural product together with the extraction solvent in a water heater at a high temperature. Specifically, the extract may be one that is heat-extracted by adding the mixed herbal material to 1 to 1,000 parts by weight of a solvent. More preferably, 200 to 300 parts by weight of the solvent may be heated and extracted by adding the mixed herbal material. In addition, according to one embodiment of the present application, the extract may be extracted for 6 to 10 hours, specifically 8 to 10 hours at a temperature of 80 to 110 ℃. When extracted at a temperature higher than this, the active ingredients may be denatured, and when extracted at a temperature lower than this, the active ingredients may not be extracted to the desired degree.

The heat-extracted extract of the present invention may be further shaken after removing the solute of the mixed herbal medicine. Specifically, shaking extraction may be performed until 1/5 to 1/4 of the added solvent remains.

In addition, the extract may be filtered. For the filtration, atmospheric filtration, reduced pressure filtration, pressure filtration, ultrafiltration, microfiltration, and reverse osmosis filtration, such as filtration methods used in the art may be used. The pore size of the filter used for filtration may be 20 to 40 μm, and if the pores of the filtration filter are larger than this, the feeling of foreign matter may increase, and if the pores of the filtration filter are smaller than this, the main active ingredient may be excluded.

In addition, the extract may be concentrated. The concentration may include methods such as concentration under reduced pressure heating, concentration under atmospheric pressure, spray drying, drum drying, freeze drying, and the like, and among them, concentration under reduced pressure may be used. Specifically, the concentrate may be concentrated to contain up to 50 to 70% by weight of solids. The concentration of solids in the extract can be measured through the weight of the solids remaining upon evaporation.

In the composition according to the present invention, green tea extract may be used in powder or liquid form, and preferably, green tea extract may be used in powder form. Specifically, the green tea extract may be a water extract of green tea, and may additionally be filtered, concentrated, sterilized, or dried. In addition, the green tea extract contains catechins, and preferably, the green tea extract may be characterized in that it contains 40% or more of catechins.

The composition according to the present invention may include a bellflower extract, and the bellflower extract may be characterized as 100% bellflower concentrate. The bellflower extract may be a water extract of bellflower, and may be additionally filtered, concentrated, sterilized, or dried. In addition, the bellflower extract may be characterized in that it contains a bellflower solid content of 60 to 80% by weight. Preferably, the solid content of bellflower may be included in an amount of 60 to 66% by weight.

The composition according to the present invention includes a propolis extract, and the propolis extract preferably contains 10% or more of total flavonoids. In addition, the propolis extract may be used in the form of a propolis mixture by mixing food additives and purified water. The propolis mixture may include 8 to 10% by weight of propolis extract, 40 to 50% by weight of glycerin, 4 to 8% by weight of polysorbate-20, and 30 to 50% by weight of purified water. Preferably, it may contain 9% by weight of propolis extract, 45% by weight of glycerin, 6% by weight of polysorbate-20, and 40% by weight of purified water. Specifically, according to one embodiment of the present invention, the method for preparing the propolis mixture may be obtained by crushing the propolis extract and pulverizing it, and completely dissolving the propolis extract in 4 times the fermented alcohol according to the mixing ratio. have. Thereafter, it may be filtered through a filter, mixed with glycerin, polysorbate-20, and purified water with the propolis liquor, completely dissolved and emulsified. In addition, a propolis mixture prepared by concentrating the mixture to remove alcohol and weighing the mixture with purified water may be used.

According to one embodiment of the present application, the food composition for improving lung function of the present application may include 1 to 3 parts by weight of green tea extract, 2.5 to 4.5 parts by weight of bellflower extract, and 0.01 to 0.1 parts by weight of propolis extract.

According to one embodiment of the present application, the food composition may include a mixed extract comprising maekmundong, sagebrush, gadungworm and tobokryeong, and in this case, the mixed extract may be 1 to 3 parts by weight. In this case, the efficacy can be maximized, and the taste and flavor of the whole food composition can be improved. Specifically, the mixed extract is 0.5 to 1.5: 0.5 to 1.5: 0.5 to 1.5: and It may be included in a weight ratio of 0.5 to 1.5. Preferably, it may be to include maekmundong, sagebrush, ragweed mugwort and tobokryeong in a weight ratio of 1:1:1:1.

The mixed extract containing maekmundong, ginseng, sagebrush, and Tobokryeong of the present invention is obtained by mixing and then extracting the herbal medicines composed of maekmundong, sasansam, gaesam, and Tobokryeong. Specifically, the extract may be extracted by adding mixed herbal ingredients including maekmundong, ginseng, wormwood and Tobokryeong to 5 to 20 parts by weight of a solvent. Preferably, the extract may be extracted with 9 parts by weight of 70% alcohol. In addition, the mixed extract may be extracted at a temperature of 60 to 80 ℃ for 10 to 14 hours, preferably it may be carried out at a temperature of 70 ℃ for 12 hours. The mixed extract may be prepared by further including the steps of additional filtration, concentration and sterilization after the extraction step. The pore size of the filter used for filtration may be 20 to 30 μm, preferably 25 μm. If the pores of the filtration filter are larger than this, the feeling of foreign body may increase, and if the pores of the filtration filter are smaller than this, the main active ingredient may be excluded. The mixed extract may be concentrated after filtration, and preferably concentration under reduced pressure may be used. Specifically, the concentrate may be one that is concentrated so that the Brix is 45 or more, preferably 50 or more. The mixed extract may be sterilized after concentration, preferably sterilized by high-temperature sterilization at a temperature of 88 to 92° C. for 60 to 65 minutes.

According to one embodiment of the present application, the food composition has a use for improving lung function. As used herein, the term “improving lung function” includes improvement in lung function and/or capacity, reduced fatigue, and improvement in oxygen saturation. As used herein, the term "improvement" is meant to include alleviation, treatment, or prevention of diseases or symptoms, and according to an experimental example of the present application, the food composition has a lung function due to the effect of excreting fine dust from the body and the effect of excreting heavy metals from the body. was found to be improved.

The effect of discharging fine dust from the body of the present invention means the effect of discharging and detoxifying the fine dust absorbed into the body, and it can be used for preventing, improving and treating diseases caused by fine dust absorbed and accumulated in the body. According to an experimental example of the present application, when the composition containing the natural extract of Example 1 was administered to a mouse induced by NiO nanoparticles, an increased decrease in cells and inhibition of cytokines appeared to relieve inflammation, discharge of fine dust in the body and / Or it could be inferred that it had a detoxifying effect.

The effect of discharging heavy metals from the body of the present invention means the effect of discharging and detoxifying the heavy metals absorbed into the body, and can be used for preventing, improving and treating diseases caused by heavy metals absorbed and accumulated in the body. The heavy metal may be any one or more selected from the group consisting of arsenic, lead, cadmium and mercury. According to an experimental example of the present application, when the composition containing the natural extract of Example 1 is administered to a mouse induced by inflammation by cadmium particles, the AST, ALT, and BUN levels are improved, and it is inferred that there is a heavy metal discharge and/or detoxification effect in the body. Could.

food composition

As used herein, "food" means a natural product or processed product containing one or more nutrients, and preferably means a state that can be directly eaten through a certain degree of processing process, , means to include all foods, food additives, functional foods and beverages. The food composition herein may preferably be a “health functional food composition”.

Health functional food composition

As used herein, the term “health functional food” refers to food manufactured and processed using raw materials or ingredients useful for the human body in accordance with the Health Functional Food Act, and is used to regulate nutrients for the structure and function of the human body or to regulate physiological processes. It refers to ingestion for the purpose of obtaining useful effects for health purposes, such as medicinal effects.

It can be used as a health functional food having an anti-inflammatory use, fine dust discharge from the body, or heavy metal discharge from the body containing the natural product complex extract of the present invention as an active ingredient.

The health functional food of the present invention can be manufactured and processed in the form of tablets, capsules, powders, granules, liquids, pills, etc. for the purpose of anti-inflammatory or body fine dust and heavy metal discharge.

In addition, the health functional food composition of the present invention may contain various flavoring agents or natural carbohydrates as additional ingredients, like a conventional food composition, in addition to containing the natural product complex extract as an active ingredient.

Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; disaccharides such as maltose, sucrose and the like; and polysaccharides such as conventional sugars such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol and erythritol. The above-mentioned flavoring agents can advantageously use natural flavoring agents (Taumatine), stevia extracts (eg rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.).

The health functional food composition may be preferably formulated as a health functional food composition by including one or more pharmaceutically acceptable carriers in addition to the active ingredients described above.

Formulations of the health functional food composition may be tablets, capsules, powders, granules, liquids, pills, and the like. For example, for formulation in the form of a tablet or capsule, the active ingredient may be combined with an orally, non-toxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water, and the like. In addition, if desired or required, suitable binders, lubricants, disintegrants and color-developers may also be included in the mixture. Suitable binders include, but are not limited to, starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tracacanth or sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, and the like. Disintegrants include, but are not limited to, starch, methyl cellulose, agar, bentonite, xanthan gum, and the like. In the composition formulated as a liquid solution, acceptable pharmaceutical carriers are sterile and biocompatible, and include saline, sterile water, Ringer's solution, buffered saline, albumin injection, dextrose solution, maltodextrin solution, glycerol, ethanol and One or more of these components may be mixed and used, and other conventional additives such as antioxidants, buffers, and bacteriostats may be added as needed.

For example, in the form of a tablet health functional food, a mixture of the natural product complex extract, which is the active ingredient of the present invention, mixed with excipients, binders, disintegrants and other additives is granulated in a conventional manner, and then a lubricant is added. Compression molding, or direct compression molding of the mixture. In addition, the health functional food in the form of tablets may contain a corrosive agent and the like, if necessary.

Among health functional foods in the form of capsules, hard capsules can be prepared by filling a conventional hard capsule with a mixture of the sea bamboo shoot extract, which is the active ingredient of the present invention, mixed with additives such as excipients, and soft capsules contain the active ingredient as an excipient. It can be prepared by filling a mixture mixed with additives such as gelatin in a capsule base such as gelatin. The soft capsules may contain a plasticizer such as glycerin or sorbitol, a colorant, a preservative, and the like, if necessary.

A health functional food in the form of a ring can be prepared by molding a mixture of the natural product complex extract, which is the active ingredient of the present invention, an excipient, a binder, a disintegrant, etc. by a conventionally known method, and if necessary, sucrose or other skins It can be zero-coated, or the surface can be coated with a substance such as starch or talc.

The health functional food in the form of granules can be prepared in granular form by a conventionally known method by mixing the natural product complex extract, which is the active ingredient of the present invention, and excipients, binders, disintegrants, etc. in granular form. agent and the like.

The health functional food may be administered by various methods such as simple ingestion, drinking, injection administration, spray administration or squeeze administration, and preferably spray administration.

The health functional food is within the level of those skilled in the art to determine the dosage of the active ingredient, and its daily dose may be, for example, 1 to 3 mL/day, but is not limited thereto, and the age of the subject to be administered , health conditions, complications, etc. can vary depending on various factors.

The health functional food may be beverages, meat, chocolate, foods, confectionery, pizza, ramen, other noodles, gums, candy, ice cream, alcoholic beverages, vitamin complexes, and health supplements, and preferably liquid tea or powdered tea. It can be prepared in the form of beverages.

The second aspect of the present application is

It provides a pharmaceutical composition for preventing or treating lung disease, comprising green tea extract, bellflower extract and propolis extract. The specific composition of the composition is as described above.

Hereinafter, the pharmaceutical composition for preventing or treating the lung disease according to the second aspect of the present application will be described in detail.

As used herein, the term “lung disease” includes inflammatory lung disease, respiratory disease caused by smoking or fine dust, lung injury, lung disease accompanied by neotosis, and the like.

As used herein, the term "inflammatory lung disease" is a lung disease accompanied by an inflammatory response, and is meant to include asthma, chronic obstructive pulmonary disease (COPD), tracheitis, and bronchitis.

As used herein, the term "respiratory disease caused by smoking or fine dust" means, in addition to including asthma and COPD, diffuse interstitial lung disease, acute respiratory distress syndrome (ARDS), and acute lung injury am. Fine dust containing various components such as carbon components such as soot and organic carbon, ionic components such as chlorine, nitric acid, ammonium, sodium, and calcium, metal components such as lead, arsenic and mercury, and polycyclic aromatic hydrocarbons such as benzopyrene It is known to cause various lung diseases such as asthma and COPD by depositing in the respiratory tract, bronchi, small airways, and alveoli (J Korean Med Assoc, 2014;57:763-768).

As used herein, the term “lung damage” refers to damage to lung cells or lung tissue caused by fine dust or the like, or a decrease in lung function due to damage to lung cells or lung tissue.

As used herein, the term "pulmonary disease accompanying netosis" includes not only COPD exemplified above, but also asthma, cystic fibrosis, respiratory syncytial virus bronchiolitis, and influenza virus infection (influenza virus). infection, bacterial pneumonia, tuberculosis, and transfusion-related acute lung injury.

The pharmaceutical composition of the present invention is effective for preventing or treating thyroid cancer. As used herein, the term "prevention" refers to any action that suppresses or delays the onset of thyroid cancer by administration of the composition of the present invention, and "treatment" refers to any action in which the symptoms due to thyroid cancer are improved or beneficially changed by the composition of the present invention. means Specifically, the extract or a fraction thereof, specifically promotes apoptosis in thyroid cancer cells, and inhibits angiogenesis, so it is effective in preventing or treating thyroid cancer with high cell mobility and invasiveness.

The pharmaceutical composition of the present invention may be administered orally or parenterally to a patient. Specifically, the administration method may include injection administration, nasal administration, transpulmonary administration, or transdermal administration, and preferably transpulmonary administration.

When the pharmaceutical composition of the present invention is used for transpulmonary administration, it may be usually used as an inhalant. The composition of the present invention can be used in the form of a known inhalant (eg, powder inhalant, inhalation suspension, inhalation solution, capsule inhalant, etc.). These types of inhalants can be prepared by filling a suitable inhaler (eg, a metered-dose inhaler, dry powder inhaler, atomizer, nebulizer, etc.) when using the pharmaceutical composition of the present invention. It may also be used as an oral spray, or may be prepared in the form of an electronic cigarette or an orally disintegrating film. Preferably, it can be used in the form of an oral spray, and when used in the form of an oral spray, not only general intake, but also oral absorption, direct action on the throat and larynx, and rapid and direct delivery and action to a large surface area of the lung through the airways through fine particle respiration This may be possible.

Hereinafter, embodiments of the present invention will be described in detail so that those of ordinary skill in the art can easily carry out the present invention.

ingredient

Green tea extract was obtained by using green tea extract powder imported from China from Mirae Biotech Co., Ltd., which was obtained by immersing green tea leaves in water for extraction, followed by filtration, concentration, and drying. For bellflower, 100% of domestic bellflower extract (60% or more solid content) in the form of a concentrate purchased from Daeho Yanghaeng Co., Ltd. was used. The bellflower extract is also obtained by immersing bellflower in water to extract, then filtration, concentration, and drying.

Propolis is liquid, and manufactured by Daeho Corporation, trade name: Daeho Propolis Mixture-WS. Specifically, the manufacturing process of the propolis mixture is as follows. The propolis extract was crushed and powdered, and the propolis extract was measured according to the mixing ratio in Table 1 below, and completely dissolved in 4 times the fermented alcohol. Thereafter, it is filtered through a filter, and glycerin, polysorbate-20 and purified water are mixed with the propolis liquor, and then completely dissolved and emulsified. The mixture was concentrated to remove alcohol, and prepared by weight with purified water.

Raw material name weight(%) note propolis extract
(as 10% of total flavonoids) 9 glycerin 45 Food Additives A.26 Polysorbate 20 6 Food additives A.289 Purified water 40 Sum 100

Preparation Example 1. Preparation of mixed extract

The mixed extract shown in Table 2 is extracted by mixing domestically grown maekmundong, ginseng, gae dungsuk, and tobokryeong in a weight ratio of 1:1:1:1 after washing and drying, and injecting 70% alcohol in a ratio of 9L per 1 kg of raw material. did. Extraction was carried out at a temperature of 70 °C and vacuum for 8 hours and 20 minutes. After extraction, it was filtered through 60 mesh, filtered to a size of 25 μm, and concentrated to a vacuum degree of -650 mmHg, a temperature of 50 °C, and brix 51.6. After filtration with 60 mesh, sterilization was performed at 90 ° C. for 1 hour to prepare a mixed extract.

Example 1. Preparation of a composition containing a natural extract

A composition containing a natural extract was prepared by blending the raw materials in the content ratio of Table 2 below.

material name appearance weight(%) green tea powder 1.8 balloon flower liquid 3.5 propolis liquid 0.3 mixed extract liquid 2.1 liquid fructose liquid 5.0 Purified water liquid 87.3 gun 100

How to purchase and manage laboratory animals

Thirty six-week-old Fischer 344 (F344) female rats were purchased from Japan SLC Inc. (Shizuoka, Japan) and acclimatized for one week before the start of the test, and then used in the experiment. After roughing, it was used for the experiment. The total number of animals was 80 animals. The breeding environment of the experimental animals was set at room temperature of 22 ± 1 °C, relative humidity of 50 ± 10%, and a 12-hour day/night cycle, and feed and drinking water were freely supplied.

Experimental Example 1. Fine dust emission confirmation experiment

1. Experimental method

Preparation of test substances

Sample 1 of Example 1 (Example 1 100%) and Example 1 diluted with drinking water (Example 1 diluted to 50%) and Sample 3 (Example 1 diluted to 25%) were prepared in rats. administered. The dose concentration of NiO nanoparticles was set through preliminary experiments. ^{In the preliminary experiment, the concentration of 300 cm 2} /mL (150 cm ² /rat) was set at a neutrophil count of 20-30% on the 15th day. Briefly describing the preparation method of the NiO nanoparticles dosing solution, a stock solution of NiO nanoparticles is prepared in distilled water at ^{a concentration of 3000 cm 2} /mL and then used with a bath sonicator (Sahan-Sonic, Seoul, Korea) was used to disperse (operation frequency of 28KHz, output power of 400 W) for 5 minutes. The dispersed stock solution was prepared by adding PBS and inactivated F344 rat serum (final serum concentration 3%) ^{to prepare a working solution [administration concentration (300 cm 2} /mL)], followed by an ultrasonic generator for 5 minutes. was dispersed using

Physicochemical characterization of NiO nanoparticles

The physicochemical characteristics of NiO nanoparticles were analyzed using the NiO nanoparticles possessed by this laboratory, so the physical and chemical characteristics data obtained previously were used. The measurement items and methods are as follows. The size of the NiO nanoparticles was measured using a transmission electron microscope (TEM), and the measurement was performed using the equipment of Dong-A University's common equipment room. The hydrodynamic size of the NiO nanoparticles was measured using a Malvern instrument by a dynamic light scattering method. The surface area of nanoparticles was measured using the BET method.

Experimental design and setting of administration groups

1) Preliminary experiment on setting NiO dose concentration

The dose concentration of NiO nanoparticles was set through preliminary experiments. As a preliminary experiment, F344 rats were acclimatized for a week, and then, after a single intrabronchial administration of NiO nanoparticles at 10, 50, 100, 150, 200, 250 cm ² /rat, an autopsy was performed on the 15th day. As a result of the preliminary experiment, the ratio of neutrophils to the total number of cells increased in a concentration-dependent manner. Among them, the concentration of 150 cm ² /rat (300 cm ² /mL) with a neutrophil ratio of 20 to 30% was set as the experimental concentration (FIG. 2).

To evaluate the efficacy of Example 1, 1.5 mL twice a day (10 a.m., 4 p.m.) at regular time intervals from 10 days before NiO nanoparticle administration Example 1 and drinking water in a total dose of 3 mL in rats It was orally administered using a sonde until the autopsy of Example 1 On the 10th day after administration, ^{0.5 mL of a NiO nanoparticle solution (150 cm 2} /mL) and a solvent control (PBS with 3% rat serum) was intrabronchially administered to rats once ( FIG. 3 ).

Experimental animals were set in 8 groups as shown in Table 3, and 5 animals were autopsied on the 8th and 15th days after intrabronchial administration in each group (Table 3). For intrabronchial administration, rats were anesthetized by inhalation with isoflurane (Primal Critical Care Bethlehem, PA, USA) using an inhalation anesthesia device (VetEquip, Pleasanton, CA, USA). After taking out the anesthetized rat, illuminating the larynx with light, visually inspecting the bronchus, inserting a 16 gauge polycarbonate catheter into the bronchus, and confirming that breathing is stable through the inserted catheter, NiO nanoparticle solution and solvent control 0.5 mL was injected. After injection, the back was lightly tapped to induce normal breathing.

Symbol oral administration NiO nanoparticles
intrabronchial administration Autopsy date (number of animals) 8 days 15th VEH drinking water PBS with
3% rat serum 5 5 B-1 sample 3 5 5 B-2 sample 2 5 5 B-3 sample 1 5 5 B-4 drinking water NiO nanoparticles
300 cm ² /mL
(150 cm ² /rat) 5 5 B-5 sample 3 5 5 B-6 sample 2 5 5 B-7 sample 1 5 5

Rat autopsy method and tissue sampling method

Autopsies were performed on days 8 and 15 after administration of NiO nanoparticles, and 4 out of 5 rats were used for inflammation analysis and quantification of NiO nanoparticles remaining in the lungs using lung lavage. One out of five rats was used for histopathological analysis. The recovery of lung lavage fluid was analyzed using the right lung lobe, and the residual amount of NiO nanoparticles was analyzed using the left lung lobe. To explain the autopsy and lung lavage analysis process of rats and the separation method of the left lung lobe, the abdominal cavity of the rat anesthetized by inhalation was opened, the abdominal vena cava was incised, and euthanized, and the thorax was opened to expose the lungs. In order to use the rat's left lung lobe for quantitative analysis of NiO nanoparticles, it was tightly tied with an elastic thread to prevent the lung lavage from entering. After that, the trachea of the experimental animal is exposed, the upper part of the trachea is partially incised, and a stainless catheter (16G) is inserted into the trachea, and then the inserted catheter is tied with an elastic thread so as not to be loosened. Connecting the syringe to the catheter, and cold PBS - was injected into ^{3 mL (Ca 2+ Mg 2+ -free} PBS, Invitrogen) in closing. While massaging the injected PBS by hand, the process of collecting the washing solution in the tube was performed by collecting it back toward the syringe, and a total of 4 recovery processes were performed. The lung lavage solution obtained first among the four recovery processes was stored separately for use in cytokine analysis, and the lavage solution 3 times thereafter was separated into another tube to secure cells in the lungs. All waste wash solutions were centrifuged at 2000 rpm for 5 minutes to separate cells and supernatant, and the supernatant of the first wash solution was transferred to a new tube and stored. Washing solution 2 to 4 times discard the supernatant and secure only the cell pellet. did. Cell pellets from 1 to 4 washes were pooled. For pooling, the cell pellet was resuspended in 1 mL of PBS containing 10% FBS. In order to confirm the change in lung weight due to Example 1 and NiO nanoparticles, the left lung lobe was separated and the weight was measured.

Analysis of waste lavage fluid

1) Cytological analysis of lung lavage fluid

Cells obtained from lung lavage were counted using a Nucleocounter (Chemometec, Allerod, Denmark) to measure the total number of cells.

2) Analysis of inflammatory cytokines in lung lavage fluid

In order to perform an analysis on inflammation of the lungs using lung lavage, the concentration of pro-inflammatory cytokines was measured using an ELISA technique. Cytokines to be analyzed were selected as cytokine-induced neutrophil chemoattractants (CINC)-3. The selected cytokines were tested using the DuoSet ELISA kit (R&D systems, Minneapolis, MN, USA) according to the protocol provided by the kit.

2. Experimental results

Results of physicochemical characterization of NiO nanoparticles

The primary size of the NiO nanoparticles was measured to be 13.6 ± 0.6 nm and the surface area was measured to be 91.8 m ² /g. And the hydration size of NiO nanoparticles was measured to be 380 ± 34, 1250 ± 173, and 353 ± 19 in distilled water, PBS, and PBS with 3% rat serum, respectively (Table 4).

NiO
nanoparticle Primary size
(nm) BET
(m ² /g) Hydrodynamic size (nm) in Distilled water PBS PBS
with 3%
rat serum 13.6 ± 0.6 91.8 380 ± 34 1250 ± 173 353 ± 19

Lung lavage fluid analysis result

1) Cytological analysis results

The total number of cells analyzed in the lung lavage is shown in FIG. 4 . As shown in FIG. 4 , the total number of cells was compared to the solvent control group (VEH) on the 15th day, the medium concentration administration group of Example 1 in which NiO nanoparticles were not administered, group B-2, and group B administered with NiO nanoparticles. -4 to B-7 groups all increased significantly. Compared to the B-4 group administered with NiO nanoparticles and fed with drinking water, it was confirmed that the number of cells in the groups B-5 to B-7 groups administered with NiO nanoparticles and Example 1 decreased as a pattern, among them, medium concentration A significant decrease was observed in group B-6 administered with Example 1. Accordingly, it was found that the increase in the number of cells induced by fine dust stimulation was alleviated in the group administered with the sample of the present invention.

2) Cytokine analysis result

CINC-3 is a cytokine-induced neutrophil chemokine that is released from leukocytes in response to various stimuli and acts as a neutrophil chemotaxis. As shown in Figure 5A, in this experiment, CINC-3 was compared with the solvent control group (VEH) on the 8th day, B-4, a group administered with NiO nanoparticles. There was a significant increase in group B-5, but there was no significant difference in other groups. In addition, compared to the B-4 group administered with NiO nanoparticles, the CINC-3 decreased from the B-5 group administered with the NiO nanoparticles and Example 1 low concentration to the B-7 group administered with the Example 1 high concentration. , in particular, a significant decrease was observed in the B-6 and B-7 groups compared to the B-4 group. As shown in FIG. 5B , on the 15th day, there was a significant increase compared to the solvent control group (VEH) in the groups B-4 to B-7, which are the NiO nanoparticles administered group. In addition, a significant decrease in CINC-3 was observed in the B-7 group, which is a group administered with NiO nanoparticles and Example 1 high concentration, compared to group B-4, which is a group administered with NiO nanoparticles. Accordingly, it was found that there was relief of inflammation induced by fine dust in the group administered with the sample of the present invention.

Experimental Example 2. Heavy metal emission confirmation experiment

1. Experimental method

Preparation of test substances

Example 1 Sample 1 (Example 1 100%) and Example 1 diluted with drinking water (Example 1 diluted to 50%) and Sample 3 (Example 1 diluted to 25%) were prepared and administered to rats did. For the cadmium solution, purchase 99.99% pure Cadmium chloride (CdCl ₂ , Sigma-Aldrich. Inc., USA) _{and dilute it with 0.9% NaCl to 1000 μg CdCl 2} /mL so that the final dose concentration is 500 μg Cd/kg bw. prepared as much as possible.

Experimental design, administration group setting

The progress of this study for verifying the heavy metal discharge efficacy of Example 1 is shown in FIG. 6 below. Example 1 Administration was administered orally until the day of autopsy in rats with a total dose of 3 mL twice a day (10 am, 4 pm) by 1.5 mL at regular time intervals from 10 days before cadmium administration. Example 1 The weight of the rat was measured 10 days after administration to convert the average body weight (145.17 g), and a CdCl ₂ solution prepared according to the measured weight [500 μg Cd/kg bw (72 μg Cd/rat)] or a solvent control ( 0.9% NaCl) 1mL was administered intraperitoneally. All rats were set up in 8 groups as shown in Table 5, and after 8 and 15 days after cadmium administration, 5 rats in each group were autopsied.

Symbol oral administration cadmium
intraperitoneal administration Autopsy date (number of animals) 8 days 15th G1 drinking water solvent control
(0.9% NaCl) 5 5 G2 sample 3 5 5 G3 sample 2 5 5 G4 sample 1 5 5 G5 drinking water 500 Cd/kg bw 5 5 G6 sample 3 5 5 G7 sample 2 5 5 G8 sample 1 5 5

Autopsy of laboratory animals, securing test samples

After intraperitoneal administration, blood, liver, and kidneys were obtained by autopsy of the experimental animals on the 8th and 15th days. After the experimental animals were under deep anesthesia using isoflurane, the abdominal cavity of the experimental animals was opened and 4 to 5 mL of blood was collected through the abdominal vena cava. Blood was centrifuged at 2000 rpm for 5 minutes to separate serum and collected and stored frozen at -80°C.

Serum biochemical analysis

For serum biochemical analysis, the serum of laboratory animals stored at -80°C was requested to SCL Healthcare, and alanine aminotransferase (ALT), aspartate transaminase (AST) and blood urea nitrogen (BUN) were analyzed.

Histopathological analysis of liver and kidney tissues

Tissues fixed in 10% neutral formalin for two days were washed with running water for 1 hour, trimmed, and then paraffin tissue treatment was performed. After the tissue treatment was completed, the embedding process was performed using a paraffin embedding machine, and it was cut to a thickness of 4 μm using a cutter and attached to a slide. Finally, for histopathological analysis of the liver and kidney, H&E stain was performed and analyzed using an optical microscope.

2. Experimental results

Serum biochemical factor analysis

The effects of cadmium exposed in the body vary depending on the amount, exposure period, and absorption route in the body. Cadmium introduced into the body is known to cause mitochondrial membrane potential and dysfunction along with oxidative stress, especially in the liver, cause liver toxicity, and then move from the liver to the kidneys to generate reactive oxygen species, causing apoptosis and cell necrosis. Therefore, in this study, ALT, AST, and BUN, which are the main indicators, were analyzed using the serum of the experimental animals in order to examine the changes in the liver and kidney toxicity-related indicators of Example 1, cadmium.

1) ALT analysis result in serum after cadmium administration

In order to confirm the change in serum ALT level according to Example 1, the administration control group (G5) and the Example 1 administration groups (G6 to G8) were compared in the cadmium administration groups (G5 to G8). As shown in Figure 7, compared with the drinking water administration group (G5) on the 8th day after cadmium administration, the natural extract-containing composition administration groups (G6 to G8) were confirmed to have a decreasing pattern of ALT levels, among which sample 2 was administered. A significant decrease was observed in the G7 group.

2) AST analysis result in serum after cadmium administration

As shown in FIG. 8 , in the cadmium administration groups (G5 to G8), the drinking water administration group (G5) had a high value compared to the non-administration control group (G1), and a significant difference was confirmed. Example 1 administration groups (G6 to G8) showed a low expression level compared to G1, and among them, the sample 2 administration group (G7) had the lowest value compared to the non-administration control group (G1), and a significant difference was confirmed.

ALT and AST are enzymes present in hepatocytes, and are released into the blood when hepatotoxicity occurs and are used as major indicators to confirm liver toxicity. In this study, a reaction to lower the ALT and AST expression in the rat blood was confirmed as a specific reaction to Example 1 except for Sample 1 in the ALT level confirmation experiment on the 8th day of administration of cadmium. Thus, in the cadmium administration groups (G5 to G8), despite the administration of cadmium, compared to the drinking water administration group (G5), it was shown that ALT and AST levels in the blood were low. In particular, the sample 2 administration group showed the greatest effect in lowering ALT and AST levels than the other two concentrations, and significant differences were confirmed between the sample 2 administration + cadmium administration group (G7) compared to the drinking water administration group (G5). However, in Example 1, the stock solution itself has higher ALT and AST levels in the blood than the non-administered control group (G1), so the effect of lowering the ALT and AST levels does not appear at the concentration of the stock solution, and this effect is in Example 1 50% concentration (G3 and G7) is considered to have the greatest effect of lowering ALT and AST levels.

3) BUN analysis result in serum after cadmium administration

BUN was measured in Example 1, in order to evaluate the abnormality of kidney function by cadmium. BUN is a urea compound that exists in the blood when urea produced after protein breakdown in the liver is combined with a specific compound. Since the kidney excretes more than 90% of BUN in the blood, it is considered as one of the main indicators to check the function of the kidney. As shown in Figure 9, the BUN value of the administration group of Example 1 is a significant decrease in the group administered with Example 1 (G2 to G4) compared to the non-administration control group (G1) in comparison between the cadmium non-administration groups (G1 to G4) observed. In addition, in comparison between the cadmium administration groups, a significant decrease was observed in the Example 1 administration group (G6 to G8) compared to the non-administration control group (G5). In addition, the BUN level of the cadmium-only control group (G5) was significantly increased compared to the cadmium non-administration control group (G1), so that damage to the kidneys caused by cadmium could be predicted.

Compared to the normal group, the level of BUN in the blood may be increased due to decreased excretion due to renal dysfunction, or the blood urea level may be lower than that of the normal group due to decreased protein degradation due to liver abnormality. In this study, it was confirmed that all of the groups administered in Example 1 (G2, 3, 4, 6, 7, 8) had lower values compared to the non-administered control group (G1). However, since the serum biochemical levels and histopathological changes of the liver measured in this study were not accompanied by ALT and AST levels, it is not determined that the BUN level is reduced due to liver toxicity according to Example 1.

In the cadmium administration groups (G5 to G8), except for the drinking water administration group (G5) to which Example 1 was not administered, the Example administration groups (G6 to G8) showed a decrease in the BUN level according to Example 1. It seems that the G5 group has a higher blood BUN level than the non-administered control group (G1) by administration of cadmium, and it is judged that the concentration of cadmium administered in this study can affect the renal function. However, since the administration of Example 1 showed the effect of reducing the BUN level in the blood of rats even in the state in which cadmium was administered, it is judged that the protective mechanism regarding the renal toxicity of cadmium is also accompanied.

Hepatic and renal histopathological analysis

As a result of observing changes in liver tissue on the 15th day after cadmium administration, no pathological changes in liver tissue were observed in the groups (G2 to G4) administered only Example 1 compared to the non-administered control group (G1). As shown in FIGS. 10 and 11 , in the cadmium alone control group (G5), although weak, vacuolation of liver tissue was observed, and this change was not observed in the cadmium + Example 1 administration group (G6 to G8). That is, in the group administered with Example 1, although weak, liver tissue was observed normally compared to the group administered with only cadmium. Accordingly, it was found that there was an effect of heavy metal detoxification in the group administered with the sample of the present invention.

Comprehensive analysis

Overall, in this study, the expression of biochemical factors in the serum according to Example 1 showed the most specific effect 8 days after cadmium administration (18 days after oral administration of Example 1). Although the expression levels of biochemical factors for liver and kidney toxicity by cadmium on day 8 after administration at the cadmium administration concentration used in this study did not show a significant difference compared to the non-administered groups (G1-4), the cadmium-administered groups ( In G5-8), since the liver showed reduced values compared to the cadmium-only control control group (G5) at all three concentrations in the liver and in the sample 3 concentrations, Example 1 was evaluated on the liver and kidney toxicity for cadmium. It is considered to have a protective pharmacological effect.

The above description of the present invention is for illustration, and those of ordinary skill in the art to which the present invention pertains can understand that it can be easily modified into other specific forms without changing the technical spirit or essential features of the present invention. will be. Therefore, it should be understood that the embodiments described above are illustrative in all respects and not restrictive. For example, each component described as a single type may be implemented in a dispersed form, and likewise components described as distributed may be implemented in a combined form.

The scope of the present invention is indicated by the following claims, and all changes or modifications derived from the meaning and scope of the claims and their equivalent concepts should be construed as being included in the scope of the present invention.

Claims (8)

A food composition for improving lung function, comprising green tea extract, bellflower extract and propolis extract.
According to claim 1,
The green tea extract, the bellflower extract, and the propolis extract are included in 1 to 3 parts by weight, 2.5 to 4.5 parts by weight, and 0.01 to 0.1 parts by weight, a food composition for improving lung function.
According to claim 1,
The food composition is a food composition for improving lung function, which further comprises a mixed extract comprising maekmundong, sasam, gadungworm and tobokryeong.
4. The method of claim 3,
The green tea extract, the bellflower extract, the propolis extract, and 1 to 3 parts by weight, 2.5 to 4.5 parts by weight, and 0.01 to 0.1 parts by weight, and 1 to 3 parts by weight of the mixed extract comprising as much as 1 to 3 parts by weight, lung A food composition for improving function.
4. The method of claim 3,
The mixed extract is 0.5 to 1.5: 0.5 to 1.5: 0.5 to 1.5: and 0.5 to 1.5 weight ratio of maekmundong, ginseng, wormwood and tobokryeong, and a food composition for improving lung function comprising a weight ratio of 0.5 to 1.5.
According to claim 1,
The lung function improvement is due to the discharge and detoxification of fine dust or heavy metals, a food composition for improving lung function.
A pharmaceutical composition for preventing or treating lung disease, comprising green tea extract, bellflower extract and propolis extract.
8. The method of claim 7,
The pharmaceutical composition for preventing or treating lung disease is a pharmaceutical composition, characterized in that it is for transpulmonary absorption.

Images